SCIENTIFIC LITERATURE · MED

Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial.

Jankovic J, Goodman I, Safirstein B, Marmon TK, Schenk DB, Koller M, Zago W, Ness DK, Griffith SG, Grundman M, Soto J, Ostrowitzki S, Boess FG, Martin-Facklam M, Quinn JF, Isaacson SH, Omidvar O, Ellenbogen A, Kinney GG.

JAMA Neurol · 2018-10-01

DOI: 10.1001/jamaneurol.2018.1487PMID: 29913017

Check source for accessResearch Support, Non-U.S. Gov't; research-article; Multicenter Study; Clinical Trial, Phase I; Randomized Controlled Trial; Journal Article; Research Support, N.I.H., ExtramuralOriginal source ↗

Research overview

Source publication and reading guides

This section identifies the original publication. Follow the source for its authors and journal.

Read the original publication ↗

Scientific assessment

Research question

Assess the question within the original study’s scope.

Methods & sample

Check the source article for study design and sample details.

Key findings

An editorially approved findings summary is not yet published for this record.

Limitations

Generalizability, bias and clinical meaning require separate assessment.

Methods, samples and clinical conclusions are not inferred from bibliographic metadata.